Impact of protein supplementation on muscle health in older men
Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults
This study is testing whether a special protein supplement can help older men build and maintain muscle better than a regular protein supplement.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 65 Years and up |
| Sex | Male |
| Sponsor | University of Nottingham Academic / other |
| Locations | 1 site (Derby, Derbyshire) |
| Trial ID | NCT06971822 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of leucine-enriched whey protein compared to isonitrogenous whey protein on muscle protein synthesis in older male adults, particularly focusing on their responses both at rest and after exercise. The research aims to address sarcopenia, a condition characterized by muscle loss and functional decline in the aging population, by evaluating how different protein supplements can enhance muscle health. Participants will receive protein supplementation and their muscle responses will be measured to determine the efficacy of the interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy male volunteers aged over 65 who are not suffering from significant health issues.
Not a fit: Patients with active cardiovascular, respiratory diseases, or metabolic disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved nutritional strategies for preventing muscle loss and enhancing physical function in older adults.
How similar studies have performed: Previous studies have shown positive outcomes with protein supplementation in older adults, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Exclusion Criteria: * A BMI \<18 or \>35 kg/m2 * Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke * Any metabolic disease * Clotting dysfunction * A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy) * Lactose intolerance * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
Where this trial is running
Derby, Derbyshire
- Royal Derby Hospital Medical School — Derby, Derbyshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Philip J Atherton — University of Nottingham
- Study coordinator: Jake Cox
- Email: mbyjc16@nottingham.ac.uk
- Phone: 07731 755075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.